Not only has Covid-19 tragically killed more than 300,000 people worldwide, it has had a severe impact on businesses, small and large, and, is likely to have a significant long-term impact on the global economy.
The pharma industry has been faced with its own challenges during this pandemic, which centre around supply chain and clinical trial disruption.
This situation has led to concerns about the global nature of active pharmaceutical ingredient (API) and generics manufacturing, which was impacted when countries like India and China went into lockdown early in the pandemic.
An early move towards a national, rather than global, approach to generics manufacturing in the future is US President Donald Trump’s move, with the administration